Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2146 to 2160 of 8804 results

  1. Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism

    In development Reference number: GID-HTG10169 Expected publication date: TBC

    HealthTech guidance
    In development

  2. Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism: draft scope consultation

    We are listening to your views on this HealthTech guidance. Comments close 14 April 2026.

    In consultation

  3. Artificial intelligence (AI) technologies to help detect prostate cancer on MRI

    In development Reference number: GID-HTE10089 Expected publication date:  12 November 2026

    Health technology evaluations
    In development

  4. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

    In development Reference number: GID-TA11545 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]

    Awaiting development Reference number: GID-TA11892 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686]

    Awaiting development Reference number: GID-TA11904 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]

    In development Reference number: GID-TA10223 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]

    In development Reference number: GID-TA11802 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]

    In development Reference number: GID-TA11818 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]

    In development Reference number: GID-TA11859 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Endoscopic submucosal dissection knives for the resection of complex colorectal polyps with suspected submucosal invasion

    In development Reference number: GID-HTE10072 Expected publication date:  19 November 2026

    Health technology evaluations
    In development

  12. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

    In development Reference number: GID-TA11764 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  13. Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]

    In development Reference number: GID-TA11334 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]

    Awaiting development Reference number: GID-TA11229 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]

    Awaiting development Reference number: GID-TA11499 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development